Most PNH patients on Empaveli avoid blood transfusions
Over the course of up to three years of treatment with Empaveli (pegcetacoplan), most people with paroxysmal nocturnal hemoglobinuria (PNH) did not require blood transfusions, according to a new analysis of clinical trial data. The analysis also indicated Empaveli led to long-term easing of fatigue and reductions in…